Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2007 (2007), Article ID 51837, 10 pages
http://dx.doi.org/10.1155/2007/51837
Research Article

Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes

1Centre for Vision Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland BT12 6BA, UK
2Department of Dermatology, School of Medicine, University of California, Sacramento, CA 95616, USA

Received 22 December 2006; Accepted 2 February 2007

Academic Editor: Subrata Chakrabarti

Copyright © 2007 Paul Canning et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Antcliff and J. Marshall, “The pathogenesis of edema in diabetic maculopathy,” Seminars in Ophthalmology, vol. 14, no. 4, pp. 223–232, 1999. View at Google Scholar
  2. C. Engler, B. Krogsaa, and H. Lund-Andersen, “Blood-retina barrier permeability and its relation to the progression of diabetic retinopathy in type 1 diabetes. An 8-year follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 229, no. 5, pp. 442–446, 1991. View at Publisher · View at Google Scholar
  3. B. Sander, M. Larsen, C. Engler et al., “Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy,” British Journal of Ophthalmology, vol. 86, no. 3, pp. 316–320, 2002. View at Publisher · View at Google Scholar
  4. G. L. Trick, J. Liggett, J. Levy et al., “Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results,” Experimental Eye Research, vol. 81, no. 1, pp. 97–102, 2005. View at Publisher · View at Google Scholar
  5. M. S. Roy, M. J. Podgor, P. Bungay, G. Grunberger, J. Carl, and D. Ellis, “Posterior vitreous fluorophotometry in diabetic patients with minimal or no retinopathy,” Retina, vol. 7, no. 3, pp. 170–176, 1987. View at Publisher · View at Google Scholar
  6. J. Cunha-Vaz, C. Lobo, J. C. Sousa, B. Oliveiros, E. Leite, and J. R. Faria de Abreu, “Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: a 7-year prospective follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 236, no. 4, pp. 264–268, 1998. View at Publisher · View at Google Scholar
  7. A. B. El-Remessy, M. A. Behzadian, G. Abou-Mohamed, T. Franklin, R. W. Caldwell, and R. B. Caldwell, “Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor,” American Journal of Pathology, vol. 162, no. 6, pp. 1995–2004, 2003. View at Google Scholar
  8. T. Qaum, Q. Xu, A. M. Joussen et al., “VEGF-initiated blood-retinal barrier breakdown in early diabetes,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413, 2001. View at Google Scholar
  9. R. H. Amin, R. N. Frank, A. Kennedy, D. Eliott, J. E. Puklin, and G. W. Abrams, “Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 38, no. 1, pp. 36–47, 1997. View at Google Scholar
  10. D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, “Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 23463–23467, 1999. View at Publisher · View at Google Scholar
  11. A. J. Barber and D. A. Antonetti, “Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats,” Investigative Ophthalmology and Visual Science, vol. 44, no. 12, pp. 5410–5416, 2003. View at Publisher · View at Google Scholar
  12. S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164 is proinflammatory in the diabetic retina,” Investigative Ophthalmology and Visual Science, vol. 44, no. 5, pp. 2155–2162, 2003. View at Publisher · View at Google Scholar
  13. L. P. Aiello, S.-E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective ß-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Google Scholar
  14. R. Rota, C. Chiavaroli, R. P. Garay, and P. Hannaert, “Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 495, no. 2-3, pp. 217–224, 2004. View at Publisher · View at Google Scholar
  15. A. K. H. Cheung, M. K. L. Fung, A. C. Y. Lo et al., “Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice,” Diabetes, vol. 54, no. 11, pp. 3119–3125, 2005. View at Google Scholar
  16. I. G. Obrosova, A. G. Minchenko, R. Vasupuram et al., “Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats,” Diabetes, vol. 52, no. 3, pp. 864–871, 2003. View at Google Scholar
  17. S. R. Thorpe and J. W. Baynes, “Maillard reaction products in tissue proteins: new products and new perspectives,” Amino Acids, vol. 25, no. 3-4, pp. 275–281, 2003. View at Publisher · View at Google Scholar
  18. H.-P. Hammes, A. Alt, T. Niwa et al., “Differential accumulation of advanced glycation end products in the course of diabetic retinopathy,” Diabetologia, vol. 42, no. 6, pp. 728–736, 1999. View at Publisher · View at Google Scholar
  19. N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P. J. Thornalley, “Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats,” Biochemical Society Transactions, vol. 31, part 6, pp. 1423–1425, 2003. View at Google Scholar
  20. A. W. Stitt, Y. M. Li, T. A. Gardiner, R. Bucala, D. B. Archer, and H. Vlassara, “Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats,” American Journal of Pathology, vol. 150, no. 2, pp. 523–531, 1997. View at Google Scholar
  21. A. W. Stitt, T. Bhaduri, C. B. T. McMullen, T. A. Gardiner, and D. B. Archer, “Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats,” Molecular Cell Biology Research Communications, vol. 3, no. 6, pp. 380–388, 2000. View at Publisher · View at Google Scholar
  22. A. W. Stitt, T. A. Gardiner, N. L. Anderson et al., “The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes,” Diabetes, vol. 51, no. 9, pp. 2826–2832, 2002. View at Google Scholar
  23. T. A. Gardiner, H. R. Anderson, and A. W. Stitt, “Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes,” Journal of Pathology, vol. 201, no. 2, pp. 328–333, 2003. View at Publisher · View at Google Scholar
  24. A. Bierhaus, M. A. Hofmann, R. Ziegler, and P. P. Nawroth, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovascular Research, vol. 37, no. 3, pp. 586–600, 1998. View at Publisher · View at Google Scholar
  25. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001. View at Publisher · View at Google Scholar
  26. A. W. Stitt, C. McGoldrick, A. Rice-McCaldin et al., “Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3,” Diabetes, vol. 54, no. 3, pp. 785–794, 2005. View at Google Scholar
  27. M. Lu, M. Kuroki, S. Amano et al., “Advanced glycation end products increase retinal vascular endothelial growth factor expression,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1219–1224, 1998. View at Google Scholar
  28. S.-I. Yamagishi, H. Yonekura, Y. Yamamoto et al., “Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8723–8730, 1997. View at Publisher · View at Google Scholar
  29. S. McFarlane, J. V. Glenn, A. M. Lichanska, D. A. C. Simpson, and A. W. Stitt, “Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium,” British Journal of Ophthalmology, vol. 89, no. 1, pp. 107–112, 2005. View at Publisher · View at Google Scholar
  30. K. Otero, F. Martínez, A. Beltrán et al., “Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells,” Biochemical Journal, vol. 359, part 3, pp. 567–574, 2001. View at Publisher · View at Google Scholar
  31. G. Leto, F. Pricci, L. Amadio et al., “Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non-enzymatic glycation and polyol pathway activation,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 448–458, 2001. View at Publisher · View at Google Scholar
  32. T. C. B. Moore, J. E. Moore, Y. Kaji et al., “The role of advanced glycation end products in retinal microvascular leukostasis,” Investigative Ophthalmology and Visual Science, vol. 44, no. 10, pp. 4457–4464, 2003. View at Publisher · View at Google Scholar
  33. D. K. Hsu, R.-Y. Yang, Z. Pan et al., “Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses,” American Journal of Pathology, vol. 156, no. 3, pp. 1073–1083, 2000. View at Google Scholar
  34. O. T. Cox, D. A. C. Simpson, A. W. Stitt, and T. A. Gardiner, “Sources of PDGF expression in murine retina and the effect of short-term diabetes,” Molecular Vision, vol. 10, no. 9, pp. 665–672, 2003. View at Google Scholar
  35. B. Brankin, M. Campbell, P. Canning, T. A. Gardiner, and A. W. Stitt, “Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium,” Experimental Eye Research, vol. 81, no. 1, pp. 22–31, 2005. View at Publisher · View at Google Scholar
  36. D. A. Simpson, S. Feeney, C. Boyle, and A. W. Stitt, “Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR,” Molecular Vision, vol. 6, pp. 178–183, 2000. View at Google Scholar
  37. A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-a suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002. View at Google Scholar
  38. A. M. Joussen, V. Poulaki, W. Qin et al., “Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo,” American Journal of Pathology, vol. 160, no. 2, pp. 501–509, 2002. View at Google Scholar
  39. A. W. Stitt and T. M. Curtis, “Advanced glycation and retinal pathology during diabetes,” Pharmacological Reports, vol. 57, supplement, pp. 156–168, 2005. View at Google Scholar
  40. P. S. Padayatti, C. Jiang, M. A. Glomb, K. Uchida, and R. H. Nagaraj, “High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells,” Current Eye Research, vol. 23, no. 2, pp. 106–115, 2001. View at Publisher · View at Google Scholar
  41. D. Yao, T. Taguchi, T. Matsumura et al., “Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription,” Cell, vol. 124, no. 2, pp. 275–286, 2006. View at Publisher · View at Google Scholar
  42. I. Giardino, D. Edelstein, and M. Brownlee, “Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 110–117, 1994. View at Google Scholar
  43. A. W. Stitt, U. Chakravarthy, D. B. Archer, and T. A. Gardiner, “Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation,” Diabetologia, vol. 38, no. 11, pp. 1271–1275, 1995. View at Publisher · View at Google Scholar
  44. D. S. Fosmark, P. A. Torjesen, B. K. Kilhovd et al., “Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus,” Metabolism, vol. 55, no. 2, pp. 232–236, 2006. View at Publisher · View at Google Scholar
  45. D. J. McKenna, J. Nelson, and A. W. Stitt, “Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells,” Life Sciences, vol. 68, no. 24, pp. 2695–2703, 2001. View at Publisher · View at Google Scholar
  46. H.-P. Hammes, D. Strodter, A. Weiss, R. G. Bretzel, K. Federlin, and M. Brownlee, “Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model,” Diabetologia, vol. 38, no. 6, pp. 656–660, 1995. View at Publisher · View at Google Scholar
  47. N. L. Alderson, M. E. Chachich, N. N. Youssef et al., “The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats,” Kidney International, vol. 63, no. 6, pp. 2123–2133, 2003. View at Publisher · View at Google Scholar
  48. R. H. Nagaraj, P. Sarkar, A. Mally, K. M. Biemel, M. O. Lederer, and P. S. Padayatti, “Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal,” Archives of Biochemistry and Biophysics, vol. 402, no. 1, pp. 110–119, 2002. View at Publisher · View at Google Scholar
  49. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, “Regulation of vascular endothelial growth factor expression by advanced glycation end products,” Journal of Biological Chemistry, vol. 276, no. 47, pp. 43836–43841, 2001. View at Publisher · View at Google Scholar
  50. J. Dumic, S. Dabelic, and M. Flögel, “Galectin-3: an open-ended story,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, no. 4, pp. 616–635, 2006. View at Publisher · View at Google Scholar
  51. H. Vlassara, R. Bucala, and L. Striker, “Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging,” Laboratory Investigation, vol. 70, no. 2, pp. 138–151, 1994. View at Google Scholar
  52. W. Zhu, H. Sano, R. Nagai, K. Fukuhara, A. Miyazaki, and S. Horiuchi, “The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1183–1188, 2001. View at Publisher · View at Google Scholar
  53. G. Pugliese, F. Pricci, G. Leto et al., “The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression,” Diabetes, vol. 49, no. 7, pp. 1249–1257, 2000. View at Google Scholar
  54. G. Pugliese, F. Pricci, C. Iacobini et al., “Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice,” The FASEB Journal, vol. 15, no. 13, pp. 2471–2479, 2001. View at Publisher · View at Google Scholar
  55. F.-T. Liu, R. J. Patterson, and J. L. Wang, “Intracellular functions of galectins,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1572, no. 2-3, pp. 263–273, 2002. View at Publisher · View at Google Scholar
  56. C. Colnot, M.-A. Ripoche, G. Milon, X. Montagutelli, P. R. Crocker, and F. Poirier, “Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice,” Immunology, vol. 94, no. 3, pp. 290–296, 1998. View at Publisher · View at Google Scholar
  57. H. Sano, D. K. Hsu, J. R. Apgar et al., “Critical role of galectin-3 in phagocytosis by macrophages,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 389–397, 2003. View at Publisher · View at Google Scholar